556 related articles for article (PubMed ID: 19369454)
21. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia.
Metsios GS; Stavropoulos-Kalinoglou A; Douglas KM; Koutedakis Y; Nevill AM; Panoulas VF; Kita M; Kitas GD
Rheumatology (Oxford); 2007 Dec; 46(12):1824-7. PubMed ID: 18032540
[TBL] [Abstract][Full Text] [Related]
22. Regression to the mean using the disease activity score in eligibility and response criteria for prescribing TNF-alpha inhibitors in adults with rheumatoid arthritis.
Greenwood MC; Rathi J; Hakim AJ; Scott DL; Doyle DV
Rheumatology (Oxford); 2007 Jul; 46(7):1165-7. PubMed ID: 17488751
[TBL] [Abstract][Full Text] [Related]
23. Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis.
Wolfe F; Rasker JJ; Boers M; Wells GA; Michaud K
Arthritis Rheum; 2007 Aug; 57(6):935-42. PubMed ID: 17665487
[TBL] [Abstract][Full Text] [Related]
24. Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981-1996.
Ward MM; Fries JF
J Rheumatol; 1998 Mar; 25(3):408-16. PubMed ID: 9517756
[TBL] [Abstract][Full Text] [Related]
25. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
[TBL] [Abstract][Full Text] [Related]
26. Costs and course of disease and function in early rheumatoid arthritis: a 3-year follow-up (the Swedish TIRA project).
Hallert E; Husberg M; Skogh T
Rheumatology (Oxford); 2006 Mar; 45(3):325-31. PubMed ID: 16287927
[TBL] [Abstract][Full Text] [Related]
27. Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid Arthritis.
McBride S; Sarsour K; White LA; Nelson DR; Chawla AJ; Johnston JA
J Rheumatol; 2011 Oct; 38(10):2141-9. PubMed ID: 21844154
[TBL] [Abstract][Full Text] [Related]
28. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions.
Helliwell PS; Taylor WJ;
J Rheumatol; 2008 Mar; 35(3):472-6. PubMed ID: 18203324
[TBL] [Abstract][Full Text] [Related]
29. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
[TBL] [Abstract][Full Text] [Related]
30. Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis.
Popa C; Netea MG; de Graaf J; van den Hoogen FH; Radstake TR; Toenhake-Dijkstra H; van Riel PL; van der Meer JW; Stalenhoef AF; Barrera P
J Rheumatol; 2009 Apr; 36(4):724-30. PubMed ID: 19273452
[TBL] [Abstract][Full Text] [Related]
31. Biological drug use: US perspectives on indications and monitoring.
Cush JJ
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv18-23. PubMed ID: 16239379
[TBL] [Abstract][Full Text] [Related]
32. Use of TNF inhibitors for RA to fall sharply.
Manag Care; 2011 Mar; 20(3):47. PubMed ID: 21485635
[No Abstract] [Full Text] [Related]
33. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.
Askling J; Baecklund E; Granath F; Geborek P; Fored M; Backlin C; Bertilsson L; Cöster L; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; van Vollenhoven R; Klareskog L; Feltelius N
Ann Rheum Dis; 2009 May; 68(5):648-53. PubMed ID: 18467516
[TBL] [Abstract][Full Text] [Related]
34. Prescription practice of biological drugs in rheumatoid arthritis during the first 3 years of post-marketing use in Denmark and Norway: criteria are becoming less stringent.
Hjardem E; Hetland ML; Østergaard M; Krogh NS; Kvien TK;
Ann Rheum Dis; 2005 Aug; 64(8):1220-3. PubMed ID: 15640272
[TBL] [Abstract][Full Text] [Related]
35. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis.
Jacobsson LT; Turesson C; Nilsson JA; Petersson IF; Lindqvist E; Saxne T; Geborek P
Ann Rheum Dis; 2007 May; 66(5):670-5. PubMed ID: 17158824
[TBL] [Abstract][Full Text] [Related]
36. Does age bias the aggressive treatment of elderly patients with rheumatoid arthritis?
Harrison MJ; Kim CA; Silverberg M; Paget SA
J Rheumatol; 2005 Jul; 32(7):1243-8. PubMed ID: 15996058
[TBL] [Abstract][Full Text] [Related]
37. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.
Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Ann Rheum Dis; 2005 Oct; 64(10):1421-6. PubMed ID: 15829572
[TBL] [Abstract][Full Text] [Related]
38. Trends in disease modifying antirheumatic drug prescription in early rheumatoid arthritis are influenced more by hospital setting than patient or disease characteristics.
Carli C; Ehlin AG; Klareskog L; Lindblad S; Montgomery SM
Ann Rheum Dis; 2006 Aug; 65(8):1102-5. PubMed ID: 16322085
[TBL] [Abstract][Full Text] [Related]
39. Prescription rheumatology practices among Mexican specialists.
Goycochea-Robles MV; Arce-Salinas CA; Guzmán-Vázquez S; Cardiel-Ríos MH
Arch Med Res; 2007 Apr; 38(3):354-9. PubMed ID: 17350489
[TBL] [Abstract][Full Text] [Related]
40. Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis.
Glossop JR; Dawes PT; Nixon NB; Mattey DL
Arthritis Res Ther; 2005; 7(6):R1227-34. PubMed ID: 16277675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
